HRT (FDA-approved, cash)
Steady downward trend from increased competition + insurance contracts.
Median pricing per treatment type over time. Mock data; production atses CMS pricing history.
Steady downward trend from increased competition + insurance contracts.
Plateau as coverage expanded but generic prices stable.
Rose 25% from 2024 as FDA shortage ended + compounding scrutiny rose.
Stable post-2024 — PA requirements driving consistent copay.
Stable. Generic medications + competitive telehealth pricing.
Slight decline. Most stable category — cheap generic.
Pricing tracking reflects market shifts in provider availability, regulatory environment, and insurance contracts. See pricing history for per-brand events.